Should I buy or sell Tenaya Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNYA shares. View TNYA analyst ratings or view top-rated stocks .

What is Tenaya Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 12 month price targets for Tenaya Therapeutics' stock. Their TNYA share price targets range from $7.00 to $20.00. On average, they anticipate the company's share price to reach $15.40 in the next twelve months. This suggests a possible upside of 259.0% from the stock's current price. View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts .

How have TNYA shares performed in 2024?

Tenaya Therapeutics' stock was trading at $3.24 at the beginning of 2024. Since then, TNYA shares have increased by 32.4% and is now trading at $4.29. View the best growth stocks for 2024 here .

Are investors shorting Tenaya Therapeutics?

Tenaya Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,090,000 shares, an increase of 21.2% from the March 15th total of 2,550,000 shares. Based on an average daily volume of 609,900 shares, the short-interest ratio is presently 5.1 days. Currently, 5.0% of the company's shares are sold short. View Tenaya Therapeutics' Short Interest .

When is Tenaya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TNYA earnings forecast .

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05.

When did Tenaya Therapeutics IPO?

Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Atticus Wealth Management LLC (0.07%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Faraz Ali, Group Gp Lp Column III and Timothy Hoey. View institutional ownership trends .

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TNYA

Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free TNYA Stock Alerts

$4.29

-0.01 (-0.23%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.14
▼
$4.40
50-Day Range: $4.30
▼
$6.80
52-Week Range: $1.66
▼
$8.09

Volume: 288,177 shs
Average Volume: 568,034 shs
Market Capitalization: $336.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.40

Get Tenaya Therapeutics alerts:

Tenaya Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 259.0% Upside
$15.40 Price Target
Short Interest: Bearish
4.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.33
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.70) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.95 out of 5 stars

Medical Sector

359th out of 918 stocks

Biological Products, Except Diagnostic Industry

52nd out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Tenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Tenaya Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.99% of the float of Tenaya Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tenaya Therapeutics has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Tenaya Therapeutics has recently increased by 21.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tenaya Therapeutics does not currently pay a dividend.
Dividend Growth
Tenaya Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNYA.

3.5

News and Social Media Coverage

News Sentiment
Tenaya Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Tenaya Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
4 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tenaya Therapeutics insiders have bought 8,038.88% more of their company's stock than they have sold. Specifically, they have bought $9,999,999.00 in company stock and sold $122,867.00 in company stock.
Percentage Held by Insiders
33.83% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tenaya Therapeutics are expected to decrease in the coming year, from ($1.70) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tenaya Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tenaya Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tenaya Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Tenaya Therapeutics Stock (NASDAQ:TNYA)

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

TNYA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TNYA Stock News Headlines

April 15, 2024 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Significant Growth in Short Interest

April 14, 2024 | finance.yahoo.com

Institutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the company

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 13, 2024 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Buy" by Analysts

April 5, 2024 | markets.businessinsider.com

Tenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating

March 29, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical Milestones

March 26, 2024 | finance.yahoo.com

20 Countries with the Highest Heart Disease Deaths Per Capita

March 21, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 21, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Tenaya Therapeutics (TNYA)

March 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sera Prognostics (SERA)

March 20, 2024 | finance.yahoo.com

Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results

March 19, 2024 | markets.businessinsider.com

Buy Rating Justified by Tenaya Therapeutics’ Strong Financials and Promising Cardiovascular Pipeline Progress

March 19, 2024 | finanznachrichten.de

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 18, 2024 | investorplace.com

TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023

March 18, 2024 | globenewswire.com

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 18, 2024 | globenewswire.com

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

February 27, 2024 | globenewswire.com

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

February 26, 2024 | globenewswire.com

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

February 18, 2024 | 247wallst.com

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

February 16, 2024 | finance.yahoo.com

TNYA Mar 2024 7.500 put

February 16, 2024 | finance.yahoo.com

TNYA Apr 2024 7.500 put

February 9, 2024 | msn.com

Tenaya Therapeutics Announces Speculative Offering Outlook

February 9, 2024 | finance.yahoo.com

Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet

February 9, 2024 | msn.com

Tenaya Therapeutics Secures $50 Million in Share Sale

February 8, 2024 | markets.businessinsider.com

Tenaya Announces Pricing Of $50 Mln Underwritten Offering; Stock Up

February 8, 2024 | finance.yahoo.com

Tenaya Therapeutics Announces Pricing of Underwritten Offering

See More Headlines

Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TNYA
CUSIP: N/A
CIK: 1858848
Web: www.tenayatherapeutics.com
Phone: 650-825-6990
Fax: N/A
Employees: 140
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.40
High Stock Price Target: $20.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +259.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-124,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -69.94%
Return on Assets: -59.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.91
Quick Ratio: 4.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.05 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 78,520,000
Free Float: 51,954,000
Market Cap: $336.85 million
Optionable: Optionable
Beta: 2.60

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Faraz Ali M.B.A. (Age 51)
CEO, Secretary & Director
Comp: $816.39k
Dr. Deepak Srivastava M.D. (Age 58)
Scientific Founder, Chairman of Scientific Advisory Board & Director
Comp: $118k
Dr. Timothy Hoey Ph.D. (Age 65)
Chief Scientific Officer
Comp: $573k
Dr. Whittemore G. Tingley M.D. (Age 56)
PH.D., Chief Medical Officer
Comp: $621.98k
Dr. Eric N. Olson Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Bruce R. Conklin
Scientific Founder
Dr. Saptarsi Haldar M.D.
Scientific Founder
Dr. Sheng Ding Ph.D.
Scientific Founder
Dr. Benoit G. Bruneau Ph.D.
Scientific Founder
Ms. Leone D. Patterson M.B.A. (Age 62)
Chief Financial & Business Officer
Comp: $448.55k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings or view top-rated stocks.
What is Tenaya Therapeutics' stock price target for 2024?: 7 Wall Street analysts have issued 12 month price targets for Tenaya Therapeutics' stock. Their TNYA share price targets range from $7.00 to $20.00. On average, they anticipate the company's share price to reach $15.40 in the next twelve months. This suggests a possible upside of 259.0% from the stock's current price.
View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts.
How have TNYA shares performed in 2024?: Tenaya Therapeutics' stock was trading at $3.24 at the beginning of 2024. Since then, TNYA shares have increased by 32.4% and is now trading at $4.29.
View the best growth stocks for 2024 here.
Are investors shorting Tenaya Therapeutics?: Tenaya Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,090,000 shares, an increase of 21.2% from the March 15th total of 2,550,000 shares. Based on an average daily volume of 609,900 shares, the short-interest ratio is presently 5.1 days. Currently, 5.0% of the company's shares are sold short.
View Tenaya Therapeutics' Short Interest.
When is Tenaya Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TNYA earnings forecast.

How were Tenaya Therapeutics' earnings last quarter?: Tenaya Therapeutics, Inc. (NASDAQ:TNYA) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05.
When did Tenaya Therapeutics IPO?: Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.
Who are Tenaya Therapeutics' major shareholders?: Tenaya Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Atticus Wealth Management LLC (0.07%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Faraz Ali, Group Gp Lp Column III and Timothy Hoey.
View institutional ownership trends.
How do I buy shares of Tenaya Therapeutics?: Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNYA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

Tenaya Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Tenaya Therapeutics Stock (NASDAQ:TNYA)

TNYA Stock Price History

TNYA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TNYA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™